UnitedHealth Group, Microsoft, offer employers free COVID-19 screening app.
View as Webpage
Managing Your Revenue Cycle's Response to COVID-19 >>
 
 
 
Subscribe
 
 
 
May 15, 2020
 
Note: HIMSS Day of Silence and Appreciation. The COVID-19 pandemic has deeply affected us all. Many of us have lost loved ones to COVID-19, and our hearts are saddened each time another life is lost to this disease. We're all working harder ... especially the hundreds of thousands of healthcare workers across the globe who are facing extraordinary challenges in fighting this disease.

We honor those lost and those working so hard to keep us well and as a show of respect and our thanks, HIMSS along with its media brands – Healthcare IT News, MobiHealthNews and Healthcare Finance News – will observe a digital day of silence and appreciation on May 18. On that day, we will pause all email, social media and digital publication notifications.

Stay strong ... stay safe ... be well.
 
 
 
 
 
Babylon COVID-19 test
 
 
Photo Credit: Babylon

British digital health company Babylon is offering COVID-19 antibody tests to anyone in the UK for its at cost price.

The FDA-approved tests, which do not have to be administered by a healthcare professional, can be taken at home and sent for analysis in a third-party lab, to determine whether or not a person has been previously infected by the virus.

Users can choose to opt-in to share information such as symptoms, location and test results to aid national research into the virus.

The tests, which cost $83, have been produced by diagnostics company Abbott and are lab-analyzed by a fully accredited Eurofins laboratory in the UK.

Research has shown that, unlike less reliable at-home rapid tests, these have 98.5% sensitivity and 99.5% specificity.

WHY IT MATTERS

When ordering the tests, patients can choose to share information about their symptoms, demographics, and testing history with researchers to provide them with invaluable information about the disease.

This is particularly important as much of the research done on COVID-19 patients has been done in hospitals on more serious cases, but little is known about the vast majority who experienced milder symptoms.

Babylon says it is committed to analyzing and publishing the aggregated information with explicit consent from testers. It has also offered to share anonymized data with the research community and Public Health England in order to provide insights into the virus and guide public policy, such as planning for future health services and safely easing lockdown policies.

THE LARGER CONTEXT

UK online doctor service Zava has also launched a COVID-19 antibody test kit with a turnaround time of one to two days, which it says is 97.5% effective at detecting the presence of COVID-19 antibodies. The service, which costs $90 and is discounted for key workers, includes a home sampling kit and lab test, with results reviewed by Zava’s GMC-registered doctors if needed.  

Meanwhile, researchers at the Institute of Global Health Innovation at Imperial College London are working with UK diagnostics firm Intelligent Fingerprinting  to develop a COVID-19 fingerprint test, which can provide results within 10 minutes without the need to be sent to a laboratory for analysis.

ON THE RECORD

Dr Olivia Morrow, who is helping lead the antibody testing effort at Babylon, said:

“With Babylon’s help, we can gain insight into how often people with only mild symptoms, or even no symptoms at all, have developed antibodies and perhaps start to answer important questions about immunity and the spread of the virus. This could help answer questions about which regions are at greater risk for breakouts, how to guide social distancing measures and better understand the natural history of the disease.”

 

 
doctor holding oxygen ambu bag over patient
 
 

About a week after Fitbit released its disappointing Q1 financials, its CEO James Park announced to CNBC that the company is looking to the ventilator space, in a temporary effort to address the coronavirus pandemic. 

The news, which was confirmed by sources at Fitbit, means major changes are in the works for the wearable company. Park told CNBC that the company will be submitting its new technology to the FDA shortly. The wearable company reportedly sought advice from doctors at some of America’s major hospitals and is considering making a sophisticated yet low-cost vent. 

Currently, certain technologies that support the coronavirus efforts, such as ventilators, have a more relaxed path through the FDA than in typical times. In March, the HHS secretary greenlighted an Emergency Use Authorization (EUA) for ventilators and other medical devices related to treating the virus. 

WHY IT MATTERS 

While there is no cure for COVID-19, medical providers can provide supportive care, according to the CDC. Ventilators are one of the ways providers have sought to treat and support patients with the coronavirus. 

Within the last few months, medical providers called on the government and companies to produce more ventilators to address the growing need. However, this surge in production could lead to a glut, the Associated Press reports.

THE LARGER TREND 

On May 7, Fitbit released its earnings summary, revealing that it missed its total revenue goal by $80.39 million. 

Last November, Google announced its plans to purchase Fitbit for $7.35 per share in cash, or a total of roughly $2.1 billion. That deal still appears to be going forward, as Google would have to pay Fitbit a termination fee of $250 million if it decides to back out, according to the document.

 
 
ADVERTISEMENT
Armis
 
 
 
The HIMSS Media team discusses how vendors, payers and policymakers are looking to answer the growing demand for mental and behavioral health services.

Keep Reading >>
 
 
 
The new tech is designed to help curb face-to-face interactions during the coronavirus pandemic.

Keep Reading >>
 
 
 
Professor Wang Linfa, Director of the Duke-NUS’ Emerging Infectious Diseases programme, and team conceived this research and invented the cPass diagnostic test.

Keep Reading >>
 
 
 
The Philadelphia-based startup was designed to help patients with organizing their prescription medications and via online support.

Keep Reading >>
 
 
 
UnitedHealth Group will maintain control over the protected health data and will manage opt-in and consent requirements.

Keep Reading >>
 
 
 
Joel Diamond, MD, CMO of 2bPrecise, discusses pharmacogenomics as a good entry point for providers in precision medicine, identifying the right medicine for better outcomes and patient satisfaction.

Keep Reading >>
 
 
By HIMSS Insights
 
There is a renaissance of wearables in digital healthcare. More and more of them, many AI-empowered, are finding their way into serious clinical trials, thus contributing to medical evidence and ultimately better patient care. But with data comes responsibility: The question of how to design a digital healthcare data space that respects the privacy of individuals while at the same time providing maximal medical benefit is more important than ever.

Download the ebook now >>
 
 
ADVERTISEMENT
HIMSS Analytics
 
HIMSS20 Digital Coverage
 
EXCLUSIVE COVERAGE
 
Now and in the weeks ahead, HIMSS20 Digital will be featuring an array of presentations that had been planned for the 2020 HIMSS Global Health Conference & Exhibition – enabling registrants to view them on demand. We'll also be showcasing stories that highlight technology's ongoing and essential role in combating the worldwide COVID-19 pandemic. This is a pivotal moment for professionals across the global health ecosystem. So check back here regularly for must-have insights about new technologies, trends, policies and other healthcare innovations.
 
 
 
 
 
2 Monument Sq., Ste 400 Portland, ME 04101
 
 
.